Dawnrays Pharmaceutical (Holdings) Limited (02348.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

Market Cap

HKD 1.48B

MomentumView details →

1D Return

−1.50%

YTD Return

−19.26%

RSI (14)

43.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

Market Cap

HKD 1.48B

RSI (14)

43.6

MomentumView details →

1D Return

−1.50%

YTD Return

−19.26%

ProfitabilityView details →

Gross Margin

46.80%

Net Margin

18.10%

EBITDA Margin

25.60%

ROE (TTM)

11.88%

ROA (TTM)

10.22%

Asset Turnover

0.56x

GrowthView details →

Revenue YoY

−5.49%

EPS YoY

−59.55%

FCF YoY

+7.87%

Revenue CAGR 3Y

−1.24%

EPS CAGR 3Y

−16.45%

EBITDA YoY

−26.24%

EarningsView details →

EPS (Actual)

HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.38x

Quick Ratio

4.88x

Div Yield

6.40%

Div Rate

HKD 0.06

Div Growth 1Y

−49.47%

Financials snapshotView financials →

Revenue (TTM)

2.25B

Net Income (TTM)

407.51M

Op. CF (TTM)

419.20M

Next earningsMar 19, 2027 →

Latest newsMore news →

Dongrui Pharmaceutical declared an interim dividend of HKD 0.015 per share for the six months ended June 2026, unchanged from the prior year.7d ago

Dongrui Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 546 million, down 13.4% year-on-year, and net profit of RMB 123 million, up 18% year-on-year.7d ago

Similar companies

Harrow Health, Inc.HROW JBM (Healthcare) Limited02161.HK Phibro Animal Health CorporationPAHC ANI Pharmaceuticals, Inc.ANIP Golden Throat Holdings Group Company Limited06896.HK Jilin Province Huinan Changlong Bio-pharmacy Company Limited08049.HK Find similar companies →

Latest newsMore news →

Dongrui Pharmaceutical declared an interim dividend of HKD 0.015 per share for the six months ended June 2026, unchanged from the prior year.7d ago Dongrui Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 546 million, down 13.4% year-on-year, and net profit of RMB 123 million, up 18% year-on-year.7d ago